Goal 3: Advance Translational Research

To facilitate innovation and accelerate research translation, knowledge dissemination, and implementation science that enhances public health.

Goal 3: Advance Translational Research

Submitted by (@rubybenjamingarner)

Facilitation of adoption of evidence-based guidelines in clinical practice for CVD risk factor identification and treatment

Multiple factors contribute to the high mortality from heart and vascular diseases in our population, most prominently genetics, patient behavior, care access, and care quality. Historically, interventions have targeted patient behaviors. Though access remains a problem, those who do receive care may not be getting the best of care based on the evidence. A focus on increasing practitioner adoption of evidence-based ...more »

Voting

1 net vote
3 up votes
2 down votes
Active

Goal 3: Advance Translational Research

Submitted by (@nhlbiforumadministrator1)

Addressing the barriers to the development, adoption of, and adherence to evidence based practices

How do we better understand patient and provider behaviors, as well as health system, community, and socio-cultural factors to effectively address the barriers to the development, adoption of, and adherence to evidence based practices?

Voting

7 net votes
23 up votes
16 down votes
Active

Goal 3: Advance Translational Research

Submitted by (@richard.mularski)

What strategies improve implementation of COPD therapy, palliation, and dyspnea management

Chronic obstructive pulmonary disease (COPD) affects over 12-24 million individuals in the U.S. where it is responsible for ~ 800,000 hospitalizations per year, and recently became America’s 3rd leading cause of death. The lag between clinical practice and treatment options described by efficacy studies to improve the quality of life, functional status, and survival in patients with COPD make it ideal for efforts in patient-centered ...more »

Voting

20 net votes
29 up votes
9 down votes
Active

Goal 3: Advance Translational Research

Submitted by (@joyce.bischoff)

To find specific medical therapies to treat the wide array of human vascular malformations and vascular tumors.

Vascular malformations and vascular tumors, together referred to as vascular anomalies, comprise a complex and wide array of diseases in which there is a fundamental disruption in blood and lymphatic vasculature. The lesions disrupt organ function, destroy tissue, cause bleeding, increase infections and can threaten life. At present, there are some medical therapies but none are specifically targeted to an underlying ...more »

Voting

18 net votes
20 up votes
2 down votes
Active

Goal 3: Advance Translational Research

Submitted by (@rwise0)

Animal Models for COPD -- Core Facilities

COPD is a major health problem with more than 140,000 deaths per year and yet there is a relative paucity of treatments that might modify the course of this disease. In part, this is due to the poor efficiency of animal models that require months of exposure to cigarette smoke. Moreover, there are no well validated small animal models of chronic mucus hypersecretion. Funding of core facilities that could both provide ...more »

Voting

20 net votes
24 up votes
4 down votes
Active

Goal 3: Advance Translational Research

Submitted by (@shahram.mori.md)

Should Allogeneic stem cell transplantation be considered as an upfront treatment in high risk double hit DLBCL?

Double-hit lymphomas (DHL’s) are high-grade B-cell lymphomas characterized by chromosomal rearrangements of MYC gene with BCL2 and less commonly, BCL6.Large analysis of patients with de novo DLBCL have shown that conventional chemotherapy does not improve the survival of DHL Aggressive upfront chemotherapy followed by autologous stem cell transplantation (ASCT) has become a standard treatment in eligible patients. Retrospective ...more »

Voting

2 net votes
3 up votes
1 down votes
Active